SCHEMBL15917708

SCHEMBL15917708

O=C(C1CC1)N1CCP(=O)(c2cc(Cc3n[nH]c(=O)c4ccccc34)ccc2F)CC1

nearest known ligand 0.93

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 20/20 0.93
▸ TNKS O95271 1/20 0.71
▸ ADORA1 P30542 1/20 0.71
▸ CDK6 Q00534 1/20 0.71
▸ PDE3A Q14432 1/20 0.71
▸ PARP6 Q2NL67 1/20 0.71
▸ PARP15 Q460N3 1/20 0.71
▸ PARP14 Q460N5 1/20 0.71
▸ PARP10 Q53GL7 1/20 0.71
▸ TIPARP Q7Z3E1 1/20 0.71
▸ PARP8 Q8N3A8 1/20 0.71
▸ PARP16 Q8N5Y8 1/20 0.71
▸ PARP12 Q9H0J9 1/20 0.71
▸ TNKS2 Q9H2K2 1/20 0.71
▸ PARP11 Q9NR21 1/20 0.71
▸ PARP2 Q9UGN5 1/20 0.71
▸ PARP4 Q9UKK3 1/20 0.71
▸ PARP3 Q9Y6F1 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29391033 1.00 PARP1 (0.93) PARP1TNKSADORA1CDK6PDE3A
SCHEMBL29393796 0.97 PARP1 (0.97) PARP1TNKSADORA1CDK6PDE3A
SCHEMBL15918116 0.97 PARP1 (0.97) PARP1TNKSADORA1CDK6PDE3A
SCHEMBL29391020 0.97 PARP1 (1.00) PARP1TNKSADORA1CDK6PDE3A
SCHEMBL14127936 0.97 PARP1 (1.00) PARP1TNKSADORA1CDK6PDE3A
SCHEMBL15917711 0.91 PARP1 (0.79) PARP1TNKSADORA1CDK6PDE3A
SCHEMBL15917821 0.88 PARP1 (0.84) PARP1TNKSADORA1CDK6PDE3A
SCHEMBL15918121 0.88 PARP1 (0.81) PARP1TNKSADORA1CDK6PDE3A
SCHEMBL15918330 0.88 PARP1 (1.00) PARP1TNKSADORA1CDK6PDE3A
SCHEMBL29390430 0.88 PARP1 (1.00) PARP1TNKSADORA1CDK6PDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11248013-B2 Tricyclic inhibitors of poly(ADP-ribose)polymerase RAKOVINA THERAPEUTICS INC. (CA) 2022-02-15 — — US claimed
EP-3925962-A1 TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE Rakovina Therapeutics Inc. (CA) 2021-12-22 — — EP claimed
EP-2714703-B1 TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE NEWGEN THERAPEUTICS INC (US) 2021-03-10 — — EP claimed
US-20180094010-A1 TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE NEWGEN THERAPEUTICS INC (US) 2018-04-05 — — US claimed
US-20170057984-A1 TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE NEWGEN THERAPEUTICS INC (US) 2017-03-02 — — US claimed
US-20140221314-A1 TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE NEWGEN THERAPEUTICS, INC. (US) 2014-08-07 — — US claimed
US-11248013-B2 Tricyclic inhibitors of poly(ADP-ribose)polymerase RAKOVINA THERAPEUTICS INC. (CA) 2022-02-15 — — US disclosed
US-11248013-B2 Tricyclic inhibitors of poly(ADP-ribose)polymerase RAKOVINA THERAPEUTICS INC. (CA) 2022-02-15 — — US disclosed
EP-3925962-A1 TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE Rakovina Therapeutics Inc. (CA) 2021-12-22 — — EP disclosed
EP-2714703-B1 TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE NEWGEN THERAPEUTICS INC (US) 2021-03-10 — — EP disclosed
US-20200299315-A1 TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE RAKOVINA THERAPEUTICS INC. (CA) 2020-09-24 — — US disclosed
US-20180094010-A1 TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE NEWGEN THERAPEUTICS INC (US) 2018-04-05 — — US disclosed
US-20170057984-A1 TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE NEWGEN THERAPEUTICS INC (US) 2017-03-02 — — US disclosed
US-20140221314-A1 TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE NEWGEN THERAPEUTICS, INC. (US) 2014-08-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221314-A1 TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE PARP1, PARP2, PARP11 PARP1 1/4885TNKS 15/4885ADORA1 1949/4885
US-20170057984-A1 TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE PARP1, PARP2, PARP11 PARP1 1/4885TNKS 15/4885ADORA1 1949/4885
US-20180094010-A1 TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE PARP1, PARP2, PARP11 PARP1 1/4885TNKS 15/4885ADORA1 1949/4885
US-11248013-B2 Tricyclic inhibitors of poly(ADP-ribose)polymerase PARP1, PARP2, PARP11 PARP1 1/4885TNKS 15/4885ADORA1 1949/4885
US-20200299315-A1 TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE PARP1, PARP2, PARP11 PARP1 1/4885TNKS 17/4885ADORA1 1688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback